About Us

Who we are

GenDelph was born from innovative research at the Polytechnic University of Valencia, Spain, where it was developed within the PROS research group at the Valencian Research Institute for Artificial Intelligence (VRAIN).

Our team consists of researchers and professionals united by a shared mission: making high-precision genomic analysis accessible to all. Our R&D is supported by the VRAIN Institute, a top research center with over two decades of software development expertise and ten years of genomic research. We bring together leading specialists in bioinformatics, genetics, software development, data science, and artificial intelligence to deliver cutting-edge genomic solutions.

Our Mission

At GenDelph we are dedicated to democratizing access to genomic analysis while pushing the boundaries of bioinformatics innovation.

We believe that genetic data analysis should be accessible to all, whether for personalized medicine or research purposes. Our approach prioritizes excellence through rigorous analysis quality, robust data privacy and security, and transparent control that empowers professionals at every step of the process.

Quality

Security

Control

In essence, our mission is to empower professionals with complete control over the genomic analysis process while maintaining the highest standards of quality, security, and transparency.

Our Roadmap

past-2022

Research and Development

A decade of genomic research and development at the PROS research group within VRAIN institute at UPV.

2023

SPIN UPV Grant

Awarded the SPIN UPV grant to accelerate product development and market innovation.

2024

Product Development

Development of a SaaS platform and MVP, achieving Technology Readiness Level 7 (TRL 7). Validated in hereditary cancer research through collaboration with the Chilean Hereditary Cancer Group and presented at the ALAG Congress in Mexico.

2025

Spin Off Consolidation

Achieved TRL 9 with expanded clinical validation and commenced commercial operations under Research Use Only (RUO) certification.

2026

Growing and Certifications

FDA certification process initiation and strategic presence planned at key healthcare conferences.

2027

European and International Expansion

Initiate CE marking certification for European market entry.

Our Team

Ana María Perez Gomez
[

Ana María Perez Gomez

CEO
Show More
Arturo Sirvent Fresneda
[

Arturo Sirvent Fresneda

CTO
Show More
Mireia Costa Sánchez
[

Mireia Costa Sánchez

Head of Genomics
Show More
Juan Alejandro Furió Agusti
[

Juan Alejandro Furió Agusti

Head of development
Show More
PROS (VRAIN UPV) Team
[

PROS (VRAIN UPV) Team

Scientific Advisory Board
Show More

Want to join us?

GenDelph is constantly evolving. If you are passionate about genomics and innovation, reach out to us to learn more about our work.

Documents illustration